Case-control evaluations of treatment and program efficacy

Epidemiologic Reviews

Volumn 16, Issue 1, 1994, Pages 90-101

  Selby, Joe V ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; CLOFIBRATE; DIURETIC AGENT; ESTROGEN; LIDOCAINE; ORAL CONTRACEPTIVE AGENT; VITAMIN;

ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; EPIDEMIOLOGY; HEALTH PROGRAM; HEALTH STATUS; HUMAN; MORBIDITY; MORTALITY; OBSERVATION; PATIENT EDUCATION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECALL; SURVIVAL;

CASE-CONTROL STUDIES; COHORT STUDIES; EPIDEMIOLOGIC METHODS; HUMANS; PROGRAM EVALUATION; TREATMENT OUTCOME;

EID: 0028363310     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a036148     Document Type: Article

References (60)

1. Comstock GW. Evaluating vaccination effectiveness and vaccine efficacy by means of casecontrol studies. Epidemiol Rev 1994; 16:77-89.
2. Weiss NS. Application of the case-control method in the evaluation of screening. Epidemiol Rev 1994;16:102-8.
3. Miettinen OS. Efficacy of intervention practice: will epidemiology provide the answers? In: Melmon KL, ed. Drug therapeutics—concepts for physicians. 2nd ed. New York, NY: Elsevier/North-Holland Publishing Company, 1981: 201-8.
4. Greenland S, Neutra R. Control of confounding in the assessment of medical technology. Lnt J Epidemiol 1980;9:361-7.
5. Feinstein AR. Epidemiologic analyses of causation: the unlearned scientific lessons of randomized trials. J Clin Epidemiol 1989;42:481-9.
6. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991;10: 577-81.
7. Mossey JM, Shapiro E. Self-rated health: a predictor of mortality among the elderly. Am J Public Health 1982;72:800-8.
8. Charlson ME, Sax FL, MacKenzie CR, et al. Assessing illness severity: does clinical judgment work? J Chronic Dis 1986;39:439-52.
9. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980;303:1038-41.
10. Bergkvist L, Adami HO, Persson I, et al. The risk of breast cancer after estrogen and estrogenprogestin replacement. N Engl J Med 1989;321: 293-7.
11. Irwin KL, Rosero-Bixby L, Oberle MW, et al. Oral contraceptives and cervical cancer risk in Costa Rica: detection bias or causal association? JAMA 1988;259:59-64.
12. Yuen J, Persson I, Bergkvist L, et al. Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for 'healthy drug-user' effect. Cancer Causes Control 1993;4:369-74.
13. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983;2: 267-71.
14. Byar DP. Problems with using observational databases to compare treatments. Stat Med 1991; 10:663-6.
15. Psaty BM, Koepsell TD, Siscovick D, et al. An approach to several problems in using large databases for population-based case-control studies of the therapeutic efficacy and safety of antihypertensive medicines. Stat Med 1991;10: 653-62.
16. Hoes AW, Grobbee DE, Lubsen J. Primary prevention in hypertension: valid conclusions from observational studies. Circulation 1991; 84(6 Suppl):VI78-83.
17. Salive ME, Mayfield JA, Weissman NW. Patient outcomes research teams and the Agency for Health Care Policy and Research. Health Serv Res 1990;25:697-708.
18. Ellwood PM. Shattuck lecture—Outcomes management: a technology of patient experience. N Engl J Med 1988;318:1549-56.
19. Epstein AM. The outcomes movement—Will it get us where we want to go? N Engl J Med 1990;323:266-70.
20. Stein REK, Gortmaker SL, Perrin EC, et al. Severity of illness: concepts and measurements. Lancet 1987;2:1506-9.
21. Knaus WA, Wagner DP, Zimmerman JE, et al. Variations in mortality and length of stay in intensive care units. Ann Intern Med 1993;118: 753-61.
22. Lemeshow S, Teres D, Klar J, et al. Mortality probability models (MPM II) based on an international cohort of intensive care unit patients. JAMA 1993;270:2478-86.
23. Horn SD, Sharkey PD, Buckle JM, et al. The relationship between severity of illness and hospital length of stay and mortality. Med Care 1991;29:305-17.
24. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63.
25. Parkerson GR Jr, Broadhead WE, Tse CKJ. The Duke Severity of Illness checklist (DUSOI) for measurement of severity and comorbidity. J Clin Epidemiol 1993;46:379-93.
26. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
27. Starfield B, Weiner J, Mumford L, et al. Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv Res 1991;26:53-74.
28. Greenfield S, Nelson EC. Recent developments and future issues in the use of health status assessment measures in clinical settings. Med Care 1992;30(5 Suppl):MS23-4.
29. Deyo RA, Carter WB. Strategies for improving and expanding the application of health status measures in clinical settings: a researcher-developer viewpoint. Med Care 1992;30(5 Suppl): MS176-86.
30. Wennberg JE, Freeman JL, Culp WJ. Are hospital services rationed in New Haven or overutilised in Boston? Lancet 1987;1:1185-9.
31. Strom BL, Miettinen OS, Melmon KL. Postmarketing studies of drug efficacy: how? Am J Med 1984;77:703-8.
32. Gray-Donald K, Kramer MS. Causality inference in observational vs experimental studies: an empirical comparison. Am J Epidemiol 1988;127: 885-92.
33. Weiss NS. Therapeutic efficacy: nonexperimental studies. In: Weiss NS. Clinical epidemiology: the study of the outcome of illness. New York, NY: Oxford University Press, 1986:72-89.
34. Selby JV, Friedman GD, Quesenberry CP Jr, et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-7.
35. Bross IDJ. Pertinency of an extraneous variable. J Chronic Dis 1967;20:487-95.
36. Bross IDJ. Spurious effects from an extraneous variable. J Chronic Dis 1966;19:637-47.
37. Winkelstein W Jr, Shillitoe EJ, Brand R, et al. Further comments on cancer of the uterine cervix, smoking, and herpesvirus infection. Am J Epidemiol 1984; 119:1-8.
38. Breslow NE, Day NE. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer, 1980:96. (IARC scientific publication no. 32).
39. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73:1-11.
40. Wacholder S. Practical considerations in choosing between the case-cohort and nested casecontrol designs. Epidemiology 1991;2:155-8.
41. Horwitz RI, Feinstein AR. The application of therapeutic-trial principles to improve the design of epidemiologic research: a case-control study suggesting that anticoagulants reduce mortality in patients with myocardial infarction. J Chronic Dis 1981;34:575-83.
42. Horwitz RI, Feinstein AR. Improved observational method for studying therapeutic efficacy: suggestive evidence that lidocaine prophylaxis prevents death in acute myocardial infarction. JAMA 1981;246:2455-9.
43. Psaty BM, Koepsell TD, LoGerfo JP, et al. Betablockers and primary prevention of coronary heart disease in patients with high blood pressure. JAMA 1989;261:2087-94.
44. Van der Meer JT, Van Wijk W, Thompson J, et al. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. Lancet 1992; 339:135-9.
45. Imperiale TF, Horwitz RI. Does prophylaxis prevent postdental infective endocarditis? A controlled evaluation of protective efficacy. Am J Med 1990;88:131-6.
46. Hutchinson TA, Polansky SM, Feinstein AR. Post-menopausal oestrogens protect against fractures of hip and distal radius: a case-control study. Lancet 1979;2:705-9.
47. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-8.
48. Paganini-Hill A, Ross RK, Gerkins VR, et al. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981;95:28-31.
49. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
50. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991;115: 455-6.
51. Mulinare J, Cordero JF, Erickson JD, et al. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988; 260:3141-5.
52. Mills JL, Rhoads GG, Simpson JL, et al. The absence of a relation between the periconceptional use of vitamins and neural-tube defects. N Engl J Med 1989;321:430-5.
53. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993;269: 1257-61.
54. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-5.
55. Recommendations for use of folic acid to reduce number of spina bifida cases and other neural tube defects. MMWR Morb Mortal Wkly Rep 1992;41(RR-14):l-7.
56. Baker F, Curbow B. The case-control study in health program evaluation. Eval Prog Planning 1991;14:263-72.
57. Thompson RS, Rivara FP, Thompson DC. A case-control study of the effectiveness of bicycle safety helmets. N Engl J Med 1989;320: 1361-7.
58. Pulungsih SP, Ittiravivongs A, et al. Assessment of the effectiveness of oral rehydration therapy against severe diarrheal dehydration. Southeast Asian J Trop Med Public Health 1992; 23:420-6.
59. Sampalis JS, Lavoie A, Williams JI, et al. Impact of on-site care, prehospital time, and level of in-hospital care on survival in severely injured patients. J Trauma 1993;34:252-61.
60. Greenland S, Watson E, Neutra RR. The casecontrol method in medical care evaluation. Med Care 1981;19:872-8.